The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview.

The human gut is home to a variety of microbes, including bacteria, viruses, fungi, eukaryotes, and archaea, which together form a complex structure. In general, the microbiota that colonizes the gastrointestinal (GI) tract plays a significant role in maintaining human health and has been implicated in the pathogenesis of a number of GI illnesses. The structural integrity and metabolic processes of the alimentary canal are physiologically influenced by the dynamic interactions between the gut and bacteria. GI dysbiosis is a result of an imbalance brought on by a decline in microbial diversity, the loss of helpful bacteria, and an increase in pathobionts. It is crucial to restoring the gut microbiota. In order to regain the eubiotic state of the microbial flora, varied methods are being researched and implemented. The use of probiotics is one strategy for re-establishing healthy gut flora. Probiotics are "living microorganisms" that improve the health of the host when provided in adequate quantities. There are two types of probiotics-bacteria and yeast-based. The review will look at and summarize the information for yeast-based Saccharomyces probiotics regarding their effectiveness and safety in treating a variety of patient diseases, particularly irritable bowel syndrome (IBS), antibiotic-associated diarrhea, and Heliobacter pylori (HpSA) infection. The only commercially accessible yeast probiotic, the Saccharomyces strain, which consists of Saccharomyces cerevisae (S. cerevisiae) and Saccharomyces boulardii (Sb), provides a number of benefits over bacterial probiotics. The significance of Sb as a potent biotherapeutic medication that may be utilized to prevent or treat a variety of GI disorders has been substantiated by several experimental studies and clinical trials.

[1]  H. Waseem,et al.  Probiotic Yeast Saccharomyces: Back to Nature to Improve Human Health , 2022, Journal of fungi.

[2]  S. Oveisi,et al.  The Effect of the Yeast Probiotic Saccharomyces boulardii on Acute Diarrhea in Children , 2021, Journal of Comprehensive Pediatrics.

[3]  N. Adu-Aryee,et al.  Antibiotic prescribing and the risk of antibiotic-associated diarrhoea in Korle Bu Teaching Hospital, Ghana: a pilot study. , 2020, Journal of infection in developing countries.

[4]  Miguel C. Teixeira,et al.  Saccharomyces boulardii: What Makes It Tick as Successful Probiotic? , 2020, Journal of fungi.

[5]  G. Su,et al.  AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. , 2020, Gastroenterology.

[6]  Qiang Xu,et al.  Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy , 2020, World journal of clinical cases.

[7]  G. Mullin,et al.  Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. , 2020, Journal of the Academy of Nutrition and Dietetics.

[8]  M. Baldeón,et al.  Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  H. Szajewska,et al.  Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update , 2020, Alimentary pharmacology & therapeutics.

[10]  T. J. Mansell,et al.  Yeasts as probiotics: mechanisms, outcomes, and future potential. , 2020, Fungal genetics and biology : FG & B.

[11]  F. F. de Melo,et al.  Pathogenesis and clinical management of Helicobacter pylori gastric infection , 2019, World journal of gastroenterology.

[12]  Jiafeng Lu,et al.  Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases , 2019, Journal of Zhejiang University-SCIENCE B.

[13]  A. Helo Treatment of Irritable Bowel Syndrome with Saccharomyces Cerevisiae: علاج القولون العصبي باستخدام خميرة البيرة , 2019, Journal of medical and pharmaceutical sciences.

[14]  W. Wong,et al.  The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy , 2019, Front. Microbiol..

[15]  S. Soliman,et al.  Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates , 2019, Pathogens.

[16]  D. Pietrella,et al.  Probiotic Cell-Free Supernatants Exhibited Anti-Inflammatory and Antioxidant Activity on Human Gut Epithelial Cells and Macrophages Stimulated with LPS , 2018, Evidence-based complementary and alternative medicine : eCAM.

[17]  A. Vohra Benefits of probiotic yeasts in human and animal health , 2017 .

[18]  S. Ng,et al.  Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. , 2017, Gastroenterology.

[19]  W. Kunze,et al.  Effects of Saccharomyces cerevisiae or boulardii yeasts on acute stress induced intestinal dysmotility , 2016, World journal of gastroenterology.

[20]  Y. Ringel,et al.  The Microbiota in Gastrointestinal Pathophysiology: Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis , 2016 .

[21]  T. Bozoğlu,et al.  Probiotics and Prebiotics , 2016 .

[22]  E. Distrutti,et al.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. , 2016, World journal of gastroenterology.

[23]  E. Quigley,et al.  THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review. , 2015, Arquivos de gastroenterologia.

[24]  H. Szajewska,et al.  Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea , 2015, Alimentary pharmacology & therapeutics.

[25]  A. Swidsinski,et al.  Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review , 2015, Clinical and experimental gastroenterology.

[26]  Liyuan Tao,et al.  [A meta-analysis of probiotics for the treatment of irritable bowel syndrome]. , 2015, Zhonghua nei ke za zhi.

[27]  S. Vermeersch,et al.  Prevalence and management of antibiotic associated diarrhea in general hospitals , 2015, BMC Infectious Diseases.

[28]  M. Bull,et al.  Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis. , 2015, Integrative medicine.

[29]  C. Neut,et al.  A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[30]  A. Kara,et al.  Saccharomyces boulardii CNCM I-745 in different clinical conditions , 2014, Expert opinion on biological therapy.

[31]  S. Sakarya,et al.  Saccharomyces boulardii expresses neuraminidase activity selective for α2,3‐linked sialic acid that decreases Helicobacter pylori adhesion to host cells , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[32]  I. Pinchuk,et al.  Effect of Helicobacter pylori on gastric epithelial cells. , 2014, World journal of gastroenterology.

[33]  M. Akhondi-Meybodi,et al.  Study of the Effect of Probiotic Saccharomyces Boulardii on the Treatment of Irritable Bowel Syndrome , 2014 .

[34]  G. Demirel,et al.  Saccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: a randomized, controlled study , 2013, Acta paediatrica.

[35]  E. Oliveira,et al.  Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. , 2013, Arquivos de gastroenterologia.

[36]  Christy A. Varughese,et al.  Antibiotic-Associated Diarrhea , 2013, Journal of pharmacy practice.

[37]  M. Łukaszewicz Saccharomyces cerevisiae var. boulardii – Probiotic Yeast , 2012 .

[38]  R. Korpela,et al.  Probiotics and irritable bowel syndrome , 2012, Microbial ecology in health and disease.

[39]  C. Pothoulakis,et al.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders , 2012, Therapeutic advances in gastroenterology.

[40]  C. Choi,et al.  A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces boulardii in Irritable Bowel Syndrome: Effect on Quality of Life , 2011, Journal of clinical gastroenterology.

[41]  L. Mcfarland Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. , 2010, World journal of gastroenterology.

[42]  C. Pothoulakis Review article: anti‐inflammatory mechanisms of action of Saccharomyces boulardii , 2009, Alimentary pharmacology & therapeutics.

[43]  S. Alam,et al.  Antibiotic associated diarrhea in children. , 2009, Indian pediatrics.

[44]  M. Sajin,et al.  A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children , 2009, Acta paediatrica.

[45]  L. Mcfarland Antibiotic-associated diarrhea: epidemiology, trends and treatment. , 2008, Future microbiology.

[46]  J. Heimbach,et al.  Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  P. Rampal,et al.  Review article: yeast as probiotics –Saccharomyces boulardii , 2007, Alimentary pharmacology & therapeutics.

[48]  A. Dursun,et al.  Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study , 2007, Helicobacter.

[49]  B. Flourié,et al.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[50]  E. Şahin,et al.  Effect of Saccharomyces boulardii in Children with Acute Gastroenteritis and Its Relationship to the Immune Response , 2007, The Journal of international medical research.

[51]  D. Forman,et al.  Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study , 2006, Gut.

[52]  B. Beşirbellioğlu,et al.  Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[53]  M. Heitkemper,et al.  Abdominal Pain Impacts Quality of Life in Women with Irritable Bowel Syndrome , 2006, The American Journal of Gastroenterology.

[54]  M. Gotteland,et al.  Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori , 2005, Acta paediatrica.

[55]  H. Szajewska,et al.  Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea in children: a randomized double‐blind placebo‐controlled trial , 2005, Alimentary pharmacology & therapeutics.

[56]  X. Badia,et al.  Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype , 2003, European journal of gastroenterology & hepatology.

[57]  A. Gasbarrini,et al.  Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study , 2002, American Journal of Gastroenterology.

[58]  P. Periti,et al.  Preclinical and Clinical Pharmacology of Biotherapeutic Agents: Saccharomyces boulardii , 2001, Journal of chemotherapy.

[59]  J. Nicoli,et al.  Antagonistic effect of Lactobacillus acidophilus, Saccharomyces boulardii and Escherichia coli combinations against experimental infections with Shigella flexneri and Salmonella enteritidis subsp. typhimurium in gnotobiotic mice , 2000, Journal of applied microbiology.

[60]  L. Mcfarland,et al.  Epidemiology, Risk Factors and Treatments for Antibiotic-Associated Diarrhea , 1998, Digestive Diseases.

[61]  C. Surawicz,et al.  Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. , 1995, The American journal of gastroenterology.

[62]  C. Surawicz,et al.  Recovery and Elimination of the Biotherapeutic Agent, Saccharomyces boulardii, in Healthy Human Volunteers , 1993, Pharmaceutical Research.

[63]  J. Hotz [Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study]. , 1990, Zeitschrift fur Gastroenterologie.

[64]  R. Ducluzeau,et al.  [Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice]. , 1982, Annales de microbiologie.

[65]  D. Graham,et al.  Current and Future Treatment of Helicobacter pylori Infections. , 2019, Advances in experimental medicine and biology.

[66]  L. Mcfarland Common Organisms and Probiotics: Saccharomyces boulardii , 2017 .

[67]  M. Vukmirovic,et al.  Beneficial properties of probiotic yeast Saccharomyces boulardii , 2016 .

[68]  R. Krishnamurthy,et al.  SACCHAROMYCES BOULARDII-A PROBIOTIC OF CHOICE , 2013 .

[69]  D. Bunout,et al.  [Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment]. , 2008, Revista medica de Chile.

[70]  Copyright © 1997, American Society for Microbiology , 1996 .

[71]  [Controlled double blind clinical trials of lyophilized Ultra-Levure. Multiple-center study by 25 physicians of 388 cases]. , 1976, Medecine & chirurgie digestives.

[72]  G. Barbara,et al.  The Immune System in Irritable Bowel Syndrome , 2011, Journal of neurogastroenterology and motility.